{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35224353", "DateRevised": {"Year": "2022", "Month": "03", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "02", "Day": "08"}], "Language": ["eng"], "ELocationID": ["10.1021/acsomega.1c06169"], "Journal": {"ISSN": "2470-1343", "JournalIssue": {"Volume": "7", "Issue": "7", "PubDate": {"Year": "2022", "Month": "Feb", "Day": "22"}}, "Title": "ACS omega", "ISOAbbreviation": "ACS Omega"}, "ArticleTitle": "Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma.", "Pagination": {"StartPage": "5929", "EndPage": "5936", "MedlinePgn": "5929-5936"}, "Abstract": {"AbstractText": ["Glioblastoma represents the most aggressive tumor of the central nervous system. Due to invasion of glioblastoma stem cells into the healthy tissue, chemoresistance, and recurrence of the tumor, it is difficult to successfully treat glioblastoma patients, which is demonstrated by the low life expectancy of patients after standard therapy treatment. Recently, we found that diisothiocyanate-derived mercapturic acids, which are isothiocyanate derivatives from plants of the Cruciferae family, provoked a decrease in glioblastoma cell viability. These findings were extended by combining diisothiocyanate-derived mercapturic acids with dinaciclib (a small-molecule inhibitor of cyclin-dependent kinases with anti-proliferative capacity) or temozolomide (TMZ, standard chemotherapeutic agent) to test whether the components have a cytotoxic effect on glioblastoma cells when the dosage is low. Here, we demonstrate that the combination of diisothiocyanate-derived mercapturic acids with dinaciclib or TMZ had an additive or even synergistic effect in the restriction of cell growth dependent on the combination of the components and the glioblastoma cell source. This strategy could be applied to inhibit glioblastoma cell growth as a therapeutic interference of glioblastoma."], "CopyrightInformation": "\u00a9 2022 The Authors. Published by American Chemical Society."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General and Visceral Surgery, Surgery Center, Ulm University Medical Center, 89081 Ulm, Germany."}], "LastName": "Xu", "ForeName": "Pengfei", "Initials": "P"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, 89081 Ulm, Germany."}], "LastName": "Westhoff", "ForeName": "Mike-Andrew", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, 89081 Ulm, Germany."}], "LastName": "Hadzalic", "ForeName": "Amina", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, 89081 Ulm, Germany."}], "LastName": "Debatin", "ForeName": "Klaus-Michael", "Initials": "KM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Chemistry, Division of Medicinal Chemistry and Microbiology, Wroclaw University of Science and Technology, Wybrze\u017ce Wyspia\u0144skiego 27, 50-370 Wroc\u0142aw, Poland."}], "LastName": "Winiarski", "ForeName": "Lukasz", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Chemistry, Division of Medicinal Chemistry and Microbiology, Wroclaw University of Science and Technology, Wybrze\u017ce Wyspia\u0144skiego 27, 50-370 Wroc\u0142aw, Poland."}], "LastName": "Oleksyszyn", "ForeName": "Jozef", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Neurosurgery, Ulm University Medical Center, Albert-Einstein-Allee 7, 89081 Ulm, Germany."}], "LastName": "Wirtz", "ForeName": "Christian Rainer", "Initials": "CR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General and Visceral Surgery, Surgery Center, Ulm University Medical Center, 89081 Ulm, Germany."}], "LastName": "Knippschild", "ForeName": "Uwe", "Initials": "U"}, {"Identifier": ["0000-0002-9596-6558"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, School of Sciences and Humanities, Nazarbayev University, Kabanbay Batyr Ave. 53, 010000 Nur-Sultan, Kazakhstan Republic."}], "LastName": "Burster", "ForeName": "Timo", "Initials": "T"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "ACS Omega", "NlmUniqueID": "101691658", "ISSNLinking": "2470-1343"}, "CoiStatement": "The authors declare no competing financial interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Jue T. R.; McDonald K. L. The challenges associated with molecular targeted therapies for glioblastoma. J. Neuro Oncol. 2016, 127, 427\u2013434. 10.1007/s11060-016-2080-6.", "ArticleIdList": ["10.1007/s11060-016-2080-6", "26900075"]}, {"Citation": "Neftel C.; Laffy J.; Filbin M. G.; Hara T.; Shore M. E.; Rahme G. J.; Richman A. R.; Silverbush D.; Shaw M. L.; Hebert C. M.; Dewitt J.; Gritsch S.; Perez E. M.; Gonzalez Castro L. N.; Lan X.; Druck N.; Rodman C.; Dionne D.; Kaplan A.; Bertalan M. S.; Small J.; Pelton K.; Becker S.; Bonal D.; Nguyen Q.-D.; Servis R. L.; Fung J. M.; Mylvaganam R.; Mayr L.; Gojo J.; Haberler C.; Geyeregger R.; Czech T.; Slavc I.; Nahed B. V.; Curry W. T.; Carter B. S.; Wakimoto H.; Brastianos P. K.; Batchelor T. T.; Stemmer-Rachamimov A.; Martinez-Lage M.; Frosch M. P.; Stamenkovic I.; Riggi N.; Rheinbay E.; Monje M.; Rozenblatt-Rosen O.; Cahill D. P.; Patel A. P.; Hunter T.; Verma I. M.; Ligon K. L.; Louis D. N.; Regev A.; Bernstein B. E.; Tirosh I.; Suv\u00e0 M. L. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 2019, 178, 835\u2013849. 10.1016/j.cell.2019.06.024.", "ArticleIdList": ["10.1016/j.cell.2019.06.024", "PMC6703186", "31327527"]}, {"Citation": "Bunse L.; Pusch S.; Bunse T.; Sahm F.; Sanghvi K.; Friedrich M.; Alansary D.; Sonner J. K.; Green E.; Deumelandt K.; Kilian M.; Neftel C.; Uhlig S.; Kessler T.; von Landenberg A.; Berghoff A. S.; Marsh K.; Steadman M.; Zhu D.; Nicolay B.; Wiestler B.; Breckwoldt M. O.; Al-Ali R.; Karcher-Bausch S.; Bozza M.; Oezen I.; Kramer M.; Meyer J.; Habel A.; Eisel J.; Poschet G.; Weller M.; Preusser M.; Nadji-Ohl M.; Thon N.; Burger M. C.; Harter P. N.; Ratliff M.; Harbottle R.; Benner A.; Schrimpf D.; Okun J.; Herold-Mende C.; Turcan S.; Kaulfuss S.; Hess-Stumpp H.; Bieback K.; Cahill D. P.; Plate K. H.; H\u00e4nggi D.; Dorsch M.; Suv\u00e1 M. L.; Niemeyer B. A.; von Deimling A.; Wick W.; Platten M. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 2018, 24, 1192\u20131203. 10.1038/s41591-018-0095-6.", "ArticleIdList": ["10.1038/s41591-018-0095-6", "29988124"]}, {"Citation": "Chen Z.; Wang Z.; Pang J. C.; Yu Y.; Bieerkehazhi S.; Lu J.; Hu T.; Zhao Y.; Xu X.; Zhang H.; Yi J. S.; Liu S.; Yang J. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Sci. Rep. 2016, 6, 29090.10.1038/srep29090.", "ArticleIdList": ["10.1038/srep29090", "PMC4932496", "27378523"]}, {"Citation": "Dinkova-Kostova A. T.; Kostov R. V. Glucosinolates and isothiocyanates in health and disease. Trends Mol. Med. 2012, 18, 337\u2013347. 10.1016/j.molmed.2012.04.003.", "ArticleIdList": ["10.1016/j.molmed.2012.04.003", "22578879"]}, {"Citation": "Singh S. V.; Singh K. Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. Carcinogenesis 2012, 33, 1833\u20131842. 10.1093/carcin/bgs216.", "ArticleIdList": ["10.1093/carcin/bgs216", "PMC3529556", "22739026"]}, {"Citation": "Trachootham D.; Zhou Y.; Zhang H.; Demizu Y.; Chen Z.; Pelicano H.; Chiao P. J.; Achanta G.; Arlinghaus R. B.; Liu J.; Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by \u03b2-phenylethyl isothiocyanate. Cancer Cell 2006, 10, 241\u2013252. 10.1016/j.ccr.2006.08.009.", "ArticleIdList": ["10.1016/j.ccr.2006.08.009", "16959615"]}, {"Citation": "Grzywa R.; Winiarski \u0141.; Psurski M.; Rudnicka A.; Wietrzyk J.; Gajda T.; Oleksyszyn J. Synthesis and biological activity of diisothiocyanate-derived mercapturic acids. Bioorg. Med. Chem. Lett. 2016, 26, 667\u2013671. 10.1016/j.bmcl.2015.11.045.", "ArticleIdList": ["10.1016/j.bmcl.2015.11.045", "26639764"]}, {"Citation": "Cwiklowska K.; Westhoff M. A.; Freisinger S.; Dwucet A.; Halatsch M. E.; Knippschild U.; Debatin K. M.; Schirmbeck R.; Winiarski L.; Oleksyszyn J.; Wirtz C. R.; Burster T. Viability of glioblastoma stem cells is effectively reduced by diisothiocyanate-derived mercapturic acids. Oncol. Lett. 2018, 16, 6181\u20136187. 10.3892/ol.2018.9347.", "ArticleIdList": ["10.3892/ol.2018.9347", "PMC6176379", "30344758"]}, {"Citation": "Pruss M.; Dwucet A.; Tanriover M.; Hlavac M.; Kast R. E.; Debatin K.-M.; Wirtz C. R.; Halatsch M.-E.; Siegelin M. D.; Westhoff M.-A.; Karpel-Massler G. Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose induces energy depletion and synergistic anti-cancer activity in glioblastoma. Br. J. Cancer 2020, 122, 1146\u20131157. 10.1038/s41416-020-0759-0.", "ArticleIdList": ["10.1038/s41416-020-0759-0", "PMC7156767", "32115576"]}, {"Citation": "Portnow J.; Badie B.; Chen M.; Liu A.; Blanchard S.; Synold T. W. The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin. Cancer Res. 2009, 15, 7092\u20137098. 10.1158/1078-0432.ccr-09-1349.", "ArticleIdList": ["10.1158/1078-0432.ccr-09-1349", "PMC2908372", "19861433"]}, {"Citation": "Schneider M.; Str\u00f6bele S.; Nonnenmacher L.; Siegelin M. D.; Tepper M.; Stroh S.; Hasslacher S.; Enzenm\u00fcller S.; Strauss G.; Baumann B.; Karpel-Massler G.; Westhoff M.-A.; Debatin K.-M.; Halatsch M.-E. A paired comparison between glioblastoma \u201cstem cells\u201d and differentiated cells. Int. J. Cancer 2016, 138, 1709\u20131718. 10.1002/ijc.29908.", "ArticleIdList": ["10.1002/ijc.29908", "26519239"]}, {"Citation": "Strobel H.; Baisch T.; Fitzel R.; Schilberg K.; Siegelin M. D.; Karpel-Massler G.; Debatin K. M.; Westhoff M. A. Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69.10.3390/biomedicines7030069.", "ArticleIdList": ["10.3390/biomedicines7030069", "PMC6783999", "31505812"]}, {"Citation": "Burster T.; Traut R.; Yermekkyzy Z.; Mayer K.; Westhoff M.-A.; Bischof J.; Knippschild U. Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. Front. Cell Dev. Biol. 2021, 9, 695325.10.3389/fcell.2021.695325.", "ArticleIdList": ["10.3389/fcell.2021.695325", "PMC8415230", "34485282"]}, {"Citation": "Burster T.; G\u00e4rtner F.; Bulach C.; Zhanapiya A.; Gihring A.; Knippschild U. Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells. Pharmaceuticals 2021, 14, 236.10.3390/ph14030236.", "ArticleIdList": ["10.3390/ph14030236", "PMC7998501", "33800301"]}, {"Citation": "Herbener V. J.; Burster T.; Goreth A.; Pruss M.; von Bandemer H.; Baisch T.; Fitzel R.; Siegelin M. D.; Karpel-Massler G.; Debatin K. M.; Westhoff M. A.; Strobel H. Considering the Experimental use of Temozolomide in Glioblastoma Research. Biomedicines 2020, 8, 151.10.3390/biomedicines8060151.", "ArticleIdList": ["10.3390/biomedicines8060151", "PMC7344626", "32512726"]}, {"Citation": "Saqub H.; Proetsch-Gugerbauer H.; Bezrookove V.; Nosrati M.; Vaquero E. M.; de Semir D.; Ice R. J.; McAllister S.; Soroceanu L.; Kashani-Sabet M.; Osorio R.; Dar A. A. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Sci. Rep. 2020, 10, 18489.10.1038/s41598-020-75578-5.", "ArticleIdList": ["10.1038/s41598-020-75578-5", "PMC7595101", "33116269"]}, {"Citation": "Jane E. P.; Premkumar D. R.; Cavaleri J. M.; Sutera P. A.; Rajasekar T.; Pollack I. F. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines. J. Pharmacol. Exp. Ther. 2016, 356, 354\u2013365. 10.1124/jpet.115.230052.", "ArticleIdList": ["10.1124/jpet.115.230052", "PMC6047232", "26585571"]}, {"Citation": "Str\u00f6bele S.; Schneider M.; Schneele L.; Siegelin M. D.; Nonnenmacher L.; Zhou S.; Karpel-Massle G.; Westhoff M.-A.; Halatsch M.-E.; Debatin K.-M. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. PLoS One 2015, 10, e013167010.1371/journal.pone.0131670.", "ArticleIdList": ["10.1371/journal.pone.0131670", "PMC4488267", "26121251"]}, {"Citation": "Westhoff M.-A.; Zhou S.; Nonnenmacher L.; Karpel-Massler G.; Jennewein C.; Schneider M.; Halatsch M.-E.; Carragher N. O.; Baumann B.; Krause A.; Simmet T.; Bachem M. G.; Wirtz C. R.; Debatin K.-M. Inhibition of NF-kappaB signaling ablates the invasive phenotype of glioblastoma. Mol. Cancer Res. 2013, 11, 1611\u20131623. 10.1158/1541-7786.mcr-13-0435-t.", "ArticleIdList": ["10.1158/1541-7786.mcr-13-0435-t", "24145173"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "11", "Day": "3"}, {"Year": "2021", "Month": "12", "Day": "24"}, {"Year": "2022", "Month": "2", "Day": "28", "Hour": "5", "Minute": "41"}, {"Year": "2022", "Month": "3", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "1", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "2", "Day": "8"}], "PublicationStatus": "epublish", "ArticleIdList": ["35224353", "PMC8867792", "10.1021/acsomega.1c06169"]}}], "PubmedBookArticle": []}